...  have reported the drug manages to thin the blood at a steady level without major fluctuations, unlike Coumadin. Patients wouldn’t need to undergo regular blood tests to check the thinness of their blood. “It’s given in a fixed dose, and has no significant food or drug interactions,” says Halperin. “It’s almost like one-size-fits-all.” The drug’s manufacturer, AstraZeneca, is seeking FDA approval to offer the drug as a treatment for people with atrial fibrillation (a potentially dangerous irregular heartbeat) and others at risk of blood clots. Experts caution however, that while Exanta may be a great improvement upon Coumadin, it won’t be perfect. The drug appears to affect liver enzymes in about 6 percent of patients, although they did fine later, Halperin says. “It will be appropriate that people who begin should have certain blood tests taken from time to time to make sure they and the medicine are getting along well ...  instead a possible new way to help people recover from the devastating effects of stroke ANCROD is derived from the venom of a pit viper snake. Researchers discovered that in people who were bitten by the snake, blood failed to clot. Based on that observation, the venom was utilized as an anticoagulant, helping blood flow more freely through vessels. What do you think? Answer below!  Tags: university of pennsylvania, new york, u.s. food and drug administration, experimental drug, atrial fibrillation, food and drug administration, blood test ...